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Elevated risks of cancers, particularly lymphoma and leukaemia,
have been well documented in sufferers of the autosomal recessive
disorder ataxia-telangiectasia (A-T). Homozygotes are rare with
estimates being of the order of 1 per 100 000 births. Heterozygote
carriers of the A-T gene are more common but remain free of
symptoms and are usually only identified when they produce a
child with A-T. Recently, however, the gene, ATM, which is
mutated in A-T patients, has been identified (Savitsky et al, 1995)
and this has led to the possibility of screening for carriers. Because
heterozygotes have in the past only been identified through their
offspring, the ability to study such individuals has been limited by
their small numbers. Despite this, however, an increased incidence
of cancer, and in particular of breast cancer, has been reported
from the USA (Swift et al, 1987, 1991) and an increase in breast
cancer has been observed in Norway, albeit based on a very small
numbers of cases (Borrensen et al, 1990). A study in Britain
(Pippard et al, 1988) found an excess of breast cancers in mothers
but not in grandmothers of A-T patients, but again it involved only
a small number of subjects.
Given that A-T heterozygotes constitute 0.2—1% of the popula-
tion, they may contribute significantly to the population burden of
breast cancer. Screening for the mutated A-T gene is a difficult
procedure, and thus it is important to establish the risk of breast
cancer in heterozygotes so that the effectiveness of genetic
screening can be determined. To this end, we have combined data
from the only two sources of data in the UK containing follow-up
information on parents and grandparents of A-T cases to estimate
the risk of breast cancer in UK heterozygotes.
MATERIALS AND METHODS
The A-T patients whose relatives have been followed up derive
from two British series. The first consists of the group previously
studied in Southampton by Pippard and her colleagues (1988). The
methods were described in detail in the earlier paper, but, briefly,
the A-T cases were ascertained by contacting all consultant derma-
tologists, paediatricians and neurologists in Britain in 1985. They
were asked to provide details of A-T cases known to them who had
been diagnosed since 1945. After permission was obtained from
the patients￿ consultants and general practitioners (GPs), the
patients￿ families were contacted and identifying details for the
parents and grandparents were requested. The cases, parents and
grandparents were then traced and flagged in the National Health
Service Central Register (NHSCR) so that information could be
obtained on emigrations, deaths and cancer registrations that
occurred in the study population.
The second group of A-T patients, assembled by LJK in Oxford,
comprised a clinical series studied by DG Harnden together with
additional cases with A-T certified as the cause of death. These
deaths were identified from an examination of all death certificates
for England and Wales for the years 1959—1978 in which the
underlying cause of death bore the codes that embrace A-T. So far
as was possible, identifying particulars were obtained from birth
certificates and Family Practitioner Committees for parents and
grandparents to be traced and flagged in the NHSCR. No contact
was made with the families.
The study of Pippard et al (1988) was taken as the primary
source, so those families that were duplicated in the Oxford series
were eliminated from the present study. No new families have
been added to these original series so they do not contain data on
families of A-T cases diagnosed after 1985.
As described in the first paper, the date of entry of an A-T
mother was the date of birth of the proband; that of a grandmother,
the birth of her child who subsequently became the mother of a
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specific case; that of fathers and grandfathers, the dates of concep-
tion (instead of dates of birth) of their offspring. The starting date
of the study was set at 1 January 1951 because of the difficulty of
tracing prior to this date of entry for some individuals. Follow-up
continued to the end of 1994.
Standard methods of analysis were used to compare the
observed numbers of deaths from all causes, all cancers and from
specific cancers with those expected from national rates (Breslow
and Day, 1987). For each sex, person-years at risk in 5-year age
groups and 5-year calendar periods were derived; expected
numbers of deaths were then obtained by multiplying the person-
years by the corresponding national mortality rates, and then
summing across relevant categories. Standardized mortality ratios
(SMRs) were calculated as the ratio of observed to expected
deaths. The 95% confidence intervals (CIs) were derived from
tables of the Poisson distribution. Separate analyses were
performed for parents and grandparents.
RESULTS
Follow-up data were available for at least one parent or grandparent
from each of 57 families from the Southampton study and an addi-
tional 44 families from the Oxford study. However, six of the latter
had to be excluded as they were already in the Southampton set.
Information for 37 families in the combined dataset was
complete in that data were available for both parents and all four
grandparents. In total, information on 178 parents and 240 grand-
parents from 95 families was available for the analysis, but four of
Table 1 Analysis of parents. Numbers of observed deaths (Obs), SMRs and 95% CIs for selected causes of death
Fathers Mothers All parents
Cause (ICD 9th revision codes) Obs SMR 95% CI Obs SMR 95% CI Obs SMR 95% CI
All malignant neoplasms (140–208) 7 1.53 0.61–3.15 4 1.26 0.34–3.21 11 1.42 0.71–2.53
Cancer of:
Stomach (151) 0 0 0–9.82 1 8.39 0.21–46.74 1 2.02 0.05–11.26
Colon (153) 0 0 0–12.30 0 0 0–17.22 0 0 0–7.17
Rectum (154) 1 4.90 0.12–27.30 0 0 0–395.84 1 3.36 0.09–18.74
Lung (162–164) 5 2.96 0.96–6.90 0 0 0–8.18 5 2.34 0.76–5.45
Female breast (174)a – – – 3 3.37 0.69–9.84 3 3.37 0.69–9.84
Kidney (191–192) 1 9.24 0.23–51.48 0 0 0–87.07 1 6.64 0.17–37.00
All causes (000–999) 17 1.08 0.63–1.73 7 0.89 0.36–1.83 24 1.02 0.65–1.51
aFor age groups < 40, 40–49, 50–59 and ³ 60 years, the observed numbers of deaths from female breast cancer were 1, 0, 1 and 1, respectively and the
expected deaths were 0.09, 0.28, 0.31 and 0.21. Information on specific cancer sites is presented for those for which there was at least one observed death or
the expected number of deaths exceeded 0.5.
Table 2 Analysis of grandparents. Numbers of observed deaths (Obs), SMRs and 95% CIs for selected causes of death
Grandfathers Grandmothers All grandparents
Cause (ICD 9th revision codes) Obs SMR 95% CI Obs SMR 95% CI Obs SMR 95% CI
All malignant neoplasms (140–208) 26 1.24 0.81–1.82 20 1.22 0.74–1.88 46 1.23 0.90–1.64
Cancer of:
Oesophagus (150) 1 1.59 0.04–8.84 1 2.35 0.06–13.07 2 1.89 0.23–6.84
Stomach (151) 4 1.75 0.48–4.47 2 1.64 0.20–5.93 6 1.71 0.63–3.72
Colon (153) 0 0 0–2.62 3 1.90 0.39–5.56 3 1.00 0.21–2.93
Rectum (154) 2 1.96 0.24–7.06 0 0 0–5.23 2 1.16 0.14–4.18
Pancreas (157) 1 1.16 0.03–6.46 2 2.77 0.34–9.99 3 1.89 0.39–5.53
Lung (162–164) 9 1.13 0.52–2.15 1 0.44 0.01–2.46 10 0.98 0.47–1.80
Female breast (174)a 3 0.89 0.18–2.59 3 0.89 0.18–2.59
Cervix uteri (180) 2 2.94 0.36–10.63 2 2.94 0.36–10.63
Ovary (183) 1 0.90 0.02–5.00 1 0.90 0.02–5.00
Prostate (185) 0 0 0–2.08 0 0 0–2.08
Bladder (188) 2 2.11 0.26–7.64 0 0 0–11.06 2 1.56 0.19–5.65
Kidney etc. (189) 0 0 0–11.26 0 0 0–18.62 0 0 0–7.02
Brain (191, 192) 0 0 0–11.86 0 0 0–13.59 0 0 0–6.33
Non-Hodgkin’s lymphoma
(200, 202.0, 202.1, 202.8) 1 3.25 0.08–18.10 0 0 0–12.65 1 1.67 0.04–9.29
Leukaemia (204–208) 0 0 0–8.03 0 0 0–9.98 0 0 0–4.45
All causes 85 0.94 0.75–1.17 71 112 0.87–1.40 158 1.02 0.86–1.19
aFor age groups < 40, 40–49, 50–59 and ³ 60 years, the observed numbers of deaths from female breast cancer were 0, 0, 1 and 2, respectively, and the
expected deaths were 0.06, 0.36, 0.79 and 2.19. Information on specific cancer sites is presented for those for which there were at least two observed deaths or
the expected number of deaths exceeded 0.5.1306 HM Inskip et al
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the grandparents died before 1 January 1951 and so were excluded.
Parents were followed up for an average of 27 years and grand-
parents for 32 years. As would be expected from their ages, more
deaths were observed among grandparents than parents. Numbers
of deaths and standardized mortality ratios for these two groups
are provided in Tables 1 (parents) and 2 (grandparents).
Among parents, there were only 11 deaths from cancer, but no
appreciable excess (SMR 1.42; 95% CI 0.71—2.53) as shown in
Table 1. Among mothers, three deaths from breast cancer were
recorded, giving a SMR of 3.37 (95% CI 0.69—9.84). There was
also no appreciable increase of deaths from cancer among grand-
parents (observed 46, SMR 1.23; 95% CI 0.90—1.64). In the case
of breast cancer, three deaths were observed among grandmothers
(SMR 0.89, 95% CI 0.18—2.59). An examination of deaths from all
causes similarly provided no remarkable findings in either parents
or grandparents (Tables 1 and 2).
Two additional breast cancers were notified to us, one in a
mother and the other in a grandmother. These cases were,
however, still alive at the end of 1994. Of the six deaths from
breast cancer, only three were notified to us as cancer registrations.
Further analysis of cancer registration data has not been
performed, mainly because cancer incidence data are only consid-
ered reliable for more recent years.
The numbers of deaths from other specific cancers were small,
though amongst those cancer sites with more than five deaths,
there were suggestions of excesses of lung cancer in fathers and
stomach cancer in grandparents, but with wide CIs. The number of
deaths from lung cancer in grandparents almost exactly equalled
the number expected on the basis of national rates, giving an SMR
of 0.98.
DISCUSSION
In this study, the available information on tracing of A-T heterozy-
gotes in Britain has been drawn together and updated. The original
Southampton study (Pippard et al, 1988) reporting on follow-up
until mid-1986 found an SMR of 11.87 (based on two deaths) for
breast cancer in mothers of A-T patients. No breast cancers were
reported in grandmothers, of whom half would be expected to be
heterozygotes. Easton (1994) reported an analysis of the same
study with follow-up to the end of 1992, by which time there had
been no further breast cancer cases. With the extended follow-up,
the expected number of cases increased and the SMR fell to 6.31.
The addition of the data from Oxford has considerably increased
the person-years at risk and the expected deaths from breast cancer
have increased threefold. In contrast, the observed number of cases
has only increased by the addition of one from the Oxford data. No
further cases of breast cancer were observed in the Southampton
study. The combined SMR of 3.37 (95% CI 0.69—9.84) in mothers
is therefore the lowest yet reported from Britain, but it is based on
a larger dataset than available before. However, the study numbers
are still small and thus the CI is wide.
Considering mothers and grandparents together, six deaths from
breast cancer were observed, compared to 4.28 expected. If the
expected number is adjusted to allow for the fact that only 50% of
grandparents are heterozygotes, the estimated relative risk (RR)
becomes 1.66 (95% CI 0.65—4.28).
These findings are compared in Table 3 with those from other
studies, following the approach used by Easton (1994). The
present study finds a much lower risk of breast cancer than either
the US or the Norwegian follow-up studies (Swift et al, 1987;
1991; Borreson et al, 1990). This is mainly because of the lack of
any increase among grandmothers. The difference is intriguing and
may be due to chance. It has also been suggested that it reflects a
susceptibility to an environmental factor that was unimportant in
the grandmother generation (Bridges and Arlett, 1992). Another
explanation is that we may have failed to trace a few grandmothers
in the NHSCR because they died from breast cancer before the
start of the study. We have no direct evidence of this, but the fact
that identifying details were easier to obtain for relatives who were
living at the time the A-T case was ascertained (mainly in the early
1980s) must make this a possibility. In this connection, it may be
relevant to note that, whereas among parents there was an indica-
tion of an excess of lung cancer, which is well known as being
related to social class, this was not found among the grandparents.
This might reflect again an underascertainment of grandparents
because of an earlier excess mortality from certain causes.
Now that the ATM gene has been identified (Savitsky et al,
1995), there have been other approaches to examining the risk of
breast cancer in heterozygotes. Recently, Athma et al (1996) have
genotyped 775 relatives in 99 A-T families, including 33 women
with breast cancer. From this they were able to derive an estimated
Table 3 Estimated risks for breast cancer in A-T heterozygotes (adapted from Easton 1994)
Reference
Breast cancer Other cancers
Study type No. Study Cases RR 95% CI Cases RR 95% CI
Epidemiological 1 Swift et al (1987) 27 6.8 2.0–22.6 67a 2.3 1.3–3.9
44b 2.9 1.5–5.5
Epidemiological 2 Swift et al (1991) 23 5.1 1.5–16.9 68 3.5 2.0–6.1
Epidemiological 3 Borresen et al (1990) 6 3.9 1.3–12.1 14 0.8 0.3–1.9
Epidemiological 4 Present study 6 1.7 0.6–4.3 51 1.4 1.0–2.0
Mutational analysis 5 Athma et al (1996)c 25 3.8 1.7–8.4
Mutational analysis 6 Fitzgerald et al (1997) 2 0.5 0.04–7.0
Both 3–6 Total 39 2.7 1.6–4.6
Both 2, 3, 4, 6 Totald 37 2.6 1.4–4.8
Epidemiological 1–4 Total 62 3.5 2.0–6.0 244 1.9 1.5–2.4
aMales. bFemales. cThis study appears to comprise cases from studies 1 and 2. dTotal for studies excluding any cases from study 1 as this study was the source
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odds ratio (OR) of 3.8 (95% CI 1.7—8.4) for the risk of breast
cancer in heterozygotes. In contrast, however, Fitzgerald et al
(1997) found no increased risk of breast cancer in young hetero-
zygote women. They performed a germ-line mutational analysis of
401 women with breast cancer diagnosed at under age 40 and
compared them with similar analyses of 202 controls. Mutations
of the A-T gene were found in 0.5% of the cases and 1% of the
controls, leading to an estimated OR of 0.5 (95% CI 0.04—6.97).
Bishop and Hopper (1997) have, however, noted that these studies
are not incompatible and argue that further detailed and large-scale
population-based studies are needed before we can be clear about
the risk in heterozygotes. These two genetic studies have been
added to Table 3 and similar summary RRs are obtained indepen-
dently of whether the hypothesis-generating study of Swift et al
(1987) is included or not. These point to an overall increase in risk
of breast cancer of approximately two- to three-fold in hetero-
zygotes but with a wide CI.
Although the findings of available studies point to an increased
risk of breast cancer among A-T heterozygotes, there continues to
be a need for additional data. This particularly applies to the
assessment of whether the risk varies with age. There are sugges-
tions that younger women are at greater risk; Swift et al (1987)
noted that two of the four breast cancers in mothers in their study
were at unusually young ages, and one of the mothers in the
present study died from this malignancy at age 38 years having
been diagnosed at the age of 34. In contrast, however, the genetic
study by Athma et al (1996) found the risk to be greatest in those
over 60 years old.
In addition to the concern about breast cancer, the possible
importance of the ATM gene in other sporadic tumours has
recently been highlighted by reports of ATM mutations in T-cell
prolymphocytic leukaemia (T-PLL) in non-A-T patients
(Stilgenbauer et al, 1997; Vorechovsky et al, 1997). Although ATM
mutations in some cases of sporadic T-PLL have been shown to be
acquired (Stoppa-Lyonnet et al, 1998), and no sporadic T-PLL
case has so far been shown to carry a germline ATM mutation, the
risk of T-PLL in A-T heterozygotes remains unknown.
The present study has added to the information available about
the cancer risk in heterozygotes. It pools the only available infor-
mation on follow-up of such individuals in the UK, but despite this
the numbers are small. However, the findings taken alongside
those from studies elsewhere do indicate an elevated risk of breast
cancer in female heterozygotes though its true magnitude is still
uncertain.
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